AAPL281.74-2.04 (-0.72%) ▼|ABBV254.31+0.96 (+0.38%) ▲|ABT92.71-1.41 (-1.50%) ▼|ACN124.74-4.24 (-3.29%) ▼|ADBE206.43+3.70 (+1.83%) ▲|AMAT694.64+67.80 (+10.82%) ▲|AMD539.49+17.91 (+3.43%) ▲|AMGN360.55+2.22 (+0.62%) ▲|AMT168.67-6.92 (-3.94%) ▼|AMZN240.14+7.45 (+3.20%) ▲|AVGO372.45+7.43 (+2.04%) ▲|AXP340.88+0.52 (+0.15%) ▲|BA214.69-2.56 (-1.18%) ▼|BAC57.88+0.00 (+0.00%) ▲|BKNG182.41+0.95 (+0.52%) ▲|BLK950.17-14.54 (-1.51%) ▼|BMY58.56+1.04 (+1.81%) ▲|BNY143.80+0.24 (+0.17%) ▲|BRK-B496.00-2.66 (-0.53%) ▼|C142.49+0.73 (+0.52%) ▲|CAT1,033.19+35.72 (+3.58%) ▲|CL92.40+0.33 (+0.36%) ▲|CMCSA24.22+1.05 (+4.53%) ▲|COF202.28-1.72 (-0.84%) ▼|COP104.20-1.76 (-1.66%) ▼|COST946.68-5.86 (-0.62%) ▼|CRM157.93-0.44 (-0.28%) ▼|CSCO117.70+3.93 (+3.45%) ▲|CVS103.58-0.76 (-0.73%) ▼|CVX168.47-2.59 (-1.51%) ▼|DE626.63+13.39 (+2.18%) ▲|DHR192.78-3.41 (-1.74%) ▼|DIS98.63-0.16 (-0.16%) ▼|DUK128.33-0.07 (-0.05%) ▼|EMR142.82-0.67 (-0.47%) ▼|FDX325.40+6.87 (+2.16%) ▲|GD348.07+1.36 (+0.39%) ▲|GE373.71+4.71 (+1.28%) ▲|GEV1,102.51+57.34 (+5.49%) ▲|GILD126.33-1.55 (-1.21%) ▼|GM77.34-0.76 (-0.97%) ▼|GOOG351.28+16.59 (+4.96%) ▲|GOOGL353.65+16.26 (+4.82%) ▲|GS1,020.21+0.60 (+0.06%) ▲|HD350.81+1.95 (+0.56%) ▲|HON227.80-15.61 (-6.41%) ▼|IBM278.00+6.37 (+2.35%) ▲|INTC131.72+3.40 (+2.65%) ▲|INTU266.40-1.32 (-0.49%) ▼|ISRG405.97+1.70 (+0.42%) ▲|JNJ258.51+3.85 (+1.51%) ▲|JPM329.39+0.34 (+0.10%) ▲|KO82.65+0.02 (+0.02%) ▲|LIN511.06-8.56 (-1.65%) ▼|LLY1,229.93+21.81 (+1.81%) ▲|LMT502.07-5.33 (-1.05%) ▼|LOW219.65-2.83 (-1.27%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA509.64+10.62 (+2.13%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.15-0.64 (-1.05%) ▼|MDT80.93-0.05 (-0.06%) ▼|META562.60+12.35 (+2.24%) ▲|MMM162.43-1.58 (-0.96%) ▼|MO74.05+0.26 (+0.35%) ▲|MRK129.38+0.72 (+0.56%) ▲|MS211.72-0.31 (-0.15%) ▼|MSFT368.57-4.40 (-1.18%) ▼|MU1,145.28+12.95 (+1.14%) ▲|NEE88.66+0.10 (+0.11%) ▲|NFLX73.78-0.03 (-0.04%) ▼|NKE41.48+0.73 (+1.79%) ▲|NOW99.97+1.63 (+1.66%) ▲|NVDA194.97+2.44 (+1.27%) ▲|ORCL147.76-0.77 (-0.52%) ▼|PEP138.68-2.71 (-1.92%) ▼|PFE24.37+0.08 (+0.33%) ▲|PG148.45-0.57 (-0.38%) ▼|PLTR115.70+2.77 (+2.45%) ▲|PM182.87+2.10 (+1.16%) ▲|QCOM188.72-0.67 (-0.35%) ▼|RTX187.33-0.66 (-0.35%) ▼|SBUX104.06-0.54 (-0.52%) ▼|SCHW90.55-0.12 (-0.13%) ▼|SO96.75-0.41 (-0.42%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.82-0.90 (-3.96%) ▼|TMO506.42-6.61 (-1.29%) ▼|TMUS173.97-8.71 (-4.77%) ▼|TSLA411.84+32.13 (+8.46%) ▲|TXN285.48+0.06 (+0.02%) ▲|UBER75.50-0.70 (-0.92%) ▼|UNH419.82-8.07 (-1.89%) ▼|UNP272.70+4.35 (+1.62%) ▲|UPS108.01-0.13 (-0.12%) ▼|USB61.28+0.37 (+0.61%) ▲|V341.65+5.42 (+1.61%) ▲|VZ44.10-2.44 (-5.24%) ▼|WFC83.51-0.35 (-0.42%) ▼|WMT114.60-1.09 (-0.94%) ▼|XOM136.06-0.48 (-0.35%) ▼|AAPL281.74-2.04 (-0.72%) ▼|ABBV254.31+0.96 (+0.38%) ▲|ABT92.71-1.41 (-1.50%) ▼|ACN124.74-4.24 (-3.29%) ▼|ADBE206.43+3.70 (+1.83%) ▲|AMAT694.64+67.80 (+10.82%) ▲|AMD539.49+17.91 (+3.43%) ▲|AMGN360.55+2.22 (+0.62%) ▲|AMT168.67-6.92 (-3.94%) ▼|AMZN240.14+7.45 (+3.20%) ▲|AVGO372.45+7.43 (+2.04%) ▲|AXP340.88+0.52 (+0.15%) ▲|BA214.69-2.56 (-1.18%) ▼|BAC57.88+0.00 (+0.00%) ▲|BKNG182.41+0.95 (+0.52%) ▲|BLK950.17-14.54 (-1.51%) ▼|BMY58.56+1.04 (+1.81%) ▲|BNY143.80+0.24 (+0.17%) ▲|BRK-B496.00-2.66 (-0.53%) ▼|C142.49+0.73 (+0.52%) ▲|CAT1,033.19+35.72 (+3.58%) ▲|CL92.40+0.33 (+0.36%) ▲|CMCSA24.22+1.05 (+4.53%) ▲|COF202.28-1.72 (-0.84%) ▼|COP104.20-1.76 (-1.66%) ▼|COST946.68-5.86 (-0.62%) ▼|CRM157.93-0.44 (-0.28%) ▼|CSCO117.70+3.93 (+3.45%) ▲|CVS103.58-0.76 (-0.73%) ▼|CVX168.47-2.59 (-1.51%) ▼|DE626.63+13.39 (+2.18%) ▲|DHR192.78-3.41 (-1.74%) ▼|DIS98.63-0.16 (-0.16%) ▼|DUK128.33-0.07 (-0.05%) ▼|EMR142.82-0.67 (-0.47%) ▼|FDX325.40+6.87 (+2.16%) ▲|GD348.07+1.36 (+0.39%) ▲|GE373.71+4.71 (+1.28%) ▲|GEV1,102.51+57.34 (+5.49%) ▲|GILD126.33-1.55 (-1.21%) ▼|GM77.34-0.76 (-0.97%) ▼|GOOG351.28+16.59 (+4.96%) ▲|GOOGL353.65+16.26 (+4.82%) ▲|GS1,020.21+0.60 (+0.06%) ▲|HD350.81+1.95 (+0.56%) ▲|HON227.80-15.61 (-6.41%) ▼|IBM278.00+6.37 (+2.35%) ▲|INTC131.72+3.40 (+2.65%) ▲|INTU266.40-1.32 (-0.49%) ▼|ISRG405.97+1.70 (+0.42%) ▲|JNJ258.51+3.85 (+1.51%) ▲|JPM329.39+0.34 (+0.10%) ▲|KO82.65+0.02 (+0.02%) ▲|LIN511.06-8.56 (-1.65%) ▼|LLY1,229.93+21.81 (+1.81%) ▲|LMT502.07-5.33 (-1.05%) ▼|LOW219.65-2.83 (-1.27%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA509.64+10.62 (+2.13%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.15-0.64 (-1.05%) ▼|MDT80.93-0.05 (-0.06%) ▼|META562.60+12.35 (+2.24%) ▲|MMM162.43-1.58 (-0.96%) ▼|MO74.05+0.26 (+0.35%) ▲|MRK129.38+0.72 (+0.56%) ▲|MS211.72-0.31 (-0.15%) ▼|MSFT368.57-4.40 (-1.18%) ▼|MU1,145.28+12.95 (+1.14%) ▲|NEE88.66+0.10 (+0.11%) ▲|NFLX73.78-0.03 (-0.04%) ▼|NKE41.48+0.73 (+1.79%) ▲|NOW99.97+1.63 (+1.66%) ▲|NVDA194.97+2.44 (+1.27%) ▲|ORCL147.76-0.77 (-0.52%) ▼|PEP138.68-2.71 (-1.92%) ▼|PFE24.37+0.08 (+0.33%) ▲|PG148.45-0.57 (-0.38%) ▼|PLTR115.70+2.77 (+2.45%) ▲|PM182.87+2.10 (+1.16%) ▲|QCOM188.72-0.67 (-0.35%) ▼|RTX187.33-0.66 (-0.35%) ▼|SBUX104.06-0.54 (-0.52%) ▼|SCHW90.55-0.12 (-0.13%) ▼|SO96.75-0.41 (-0.42%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.82-0.90 (-3.96%) ▼|TMO506.42-6.61 (-1.29%) ▼|TMUS173.97-8.71 (-4.77%) ▼|TSLA411.84+32.13 (+8.46%) ▲|TXN285.48+0.06 (+0.02%) ▲|UBER75.50-0.70 (-0.92%) ▼|UNH419.82-8.07 (-1.89%) ▼|UNP272.70+4.35 (+1.62%) ▲|UPS108.01-0.13 (-0.12%) ▼|USB61.28+0.37 (+0.61%) ▲|V341.65+5.42 (+1.61%) ▲|VZ44.10-2.44 (-5.24%) ▼|WFC83.51-0.35 (-0.42%) ▼|WMT114.60-1.09 (-0.94%) ▼|XOM136.06-0.48 (-0.35%) ▼|
24.2 C
New York
Tuesday, June 30, 2026

Tag: study

newssourceFORcompanyinformationcontent1releasesmarket

Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans

HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased...

Academic friend or foe? Yugo research reveals how students supercharge their studies with AI

Despite academic advantages, substantial fears remain about AI's impact LONDON, June 19, 2025 /PRNewswire/ -- As universities grapple with how to effectively police AI, new Yugo...

ARROW INDUSTRIAL SOLUTIONS RELEASES CASE STUDY SHOWCASING SCALABLE MACHINE SAFEGUARDING STRATEGIES FOR MULTI-PLANT MANUFACTURERS

Arrow Industrial Solutions, a subsidiary of Clarion Safety Systems, applies a turnkey approach to machine safeguarding that helps organizations to reduce risk, improve compliance,...

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has...

MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®

TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI, a global leader in AI-powered cardiovascular diagnostics, announced today that the Pharmaceuticals and Medical Devices Agency...

Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight

According to DelveInsight's analysis, the current developmental pipeline for osteoarthritis is robust, with several companies initiating clinical trials to investigate new treatment options or...

Huxley Medical Shares New Data at SLEEP Demonstrating Breadth of Clinical Insights Enabled by SANSA Diagnostic Platform

SEATTLE, June 18, 2025 /PRNewswire/ -- Huxley Medical, a commercial-stage medical technology firm focused on streamlining detection of sleep and heart disorders, announced the...

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a one-for-thirty reverse stock split (the “Reverse Stock Split”) of the company’s common stock, par value $0.00001, which will become effective at 12:01 a.m. Eastern Time on Tuesday, June 24, 2025. The company’s common stock will continue to trade under its current trading symbol, CLRB, on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis when the market opens on Tuesday, June 24, 2025, with the new CUSIP number 15117F880.

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with...

Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors

407 ETR and Canadian Wildlife Federation expand pollinator habitat restoration along Highway 407 ETR corridor and beyond

Restoration work surpasses goal, reaching nearly 16 hectares—the equivalent of 30 football fields TORONTO, June 18, 2025 /CNW/ - In recognition of Pollinator Week, 407...

Catalyst Clinical Research Wins the Excellence in Clinical Trial Management Award

Fierce CRO Awards acknowledge the company's focus to deliver for our customers  WILMINGTON, N.C., June 18, 2025 /PRNewswire/ -- Catalyst Clinical Research today proudly announces it...

Construction Adhesives Market is expected to generate a revenue of USD 35.05 Billion by 2032, Globally, at 11.5% CAGR: Verified Market Research®

The Construction Adhesives Market presents significant growth opportunities, especially in Asia-Pacific, where infrastructure expansion and urbanization are at their peak. Market drivers such as...

Lindus Health Named Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category

BOSTON, June 18, 2025 /PRNewswire/ -- Lindus Health, the anti-CRO running radically faster, more reliable clinical trials, has been honored the winner in the...

Thermoplastic Elastomers Market Size Projected to Hit $40.9 billion, Globally, by 2030- Exclusive Study by The Research Insights

CHICAGO, June 18, 2025 /PRNewswire/ -- The global thermoplastic elastomers market is projected to be valued at USD 26.6 billion in 2024 and reach USD...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers